Application of CVF, C1-inhibitor, C3-inhibition through soluble CR1 or C3-deletion, as well as immunoglobulin treatment, have all shown protective effects in adult stroke animal models (157), suggesting that complement-targeted therapy could prove effective in neonatal HI and needs further investigation. Here, CR1 is linked to stroke disorder.